Nuveen LLC Purchases Shares of 149,961 Prothena Corporation plc $PRTA

Key Points

• Nuveen LLC has acquired 149,961 shares of Prothena Corporation plc, valued at approximately $1,856,000, representing 0.28% of the company's total shares.
• Several institutional investors, including MIRAE ASSET GLOBAL and ProShare Advisors LLC, have increased their stakes in Prothena, highlighting significant investor interest in the biotechnology company.
• Prothena's recent earnings report showed a loss of ($1.86) EPS, below the consensus estimate, with analysts forecasting a negative outlook for the company this fiscal year.

Nuveen LLC purchased a new stake in Prothena Corporation plc (NASDAQ:PRTA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 149,961 shares of the biotechnology company's stock, valued at approximately $1,856,000. Nuveen LLC owned 0.28% of Prothena as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Prothena by 4,626.0% in the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 5,875 shares during the period. Cambridge Investment Research Advisors Inc. bought a new position in Prothena in the 1st quarter valued at about $126,000. Cary Street Partners Financial LLC bought a new position in Prothena in the 4th quarter valued at about $173,000. Raymond James Financial Inc. bought a new position in Prothena in the 4th quarter valued at about $182,000. Finally, Chicago Partners Investment Group LLC increased its holdings in shares of Prothena by 29.6% during the first quarter. Chicago Partners Investment Group LLC now owns 14,512 shares of the biotechnology company's stock worth $180,000 after purchasing an additional 3,315 shares during the period. 97.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PRTA. Jefferies Financial Group cut shares of Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a report on Tuesday, May 27th. Bank of America reaffirmed an "underperform" rating on shares of Prothena in a report on Wednesday, May 28th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Prothena in a report on Friday, June 20th. JMP Securities reduced their price target on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research report on Tuesday, May 27th. Finally, Chardan Capital reiterated a "buy" rating and set a $18.00 price target on shares of Prothena in a research report on Thursday. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Prothena has an average rating of "Hold" and a consensus target price of $22.00.

Prothena Stock Performance

Shares of NASDAQ:PRTA traded down $0.04 during mid-day trading on Monday, reaching $8.20. 903,119 shares of the company's stock were exchanged, compared to its average volume of 1,183,799. The firm has a market capitalization of $441.41 million, a price-to-earnings ratio of -1.45 and a beta of -0.04. The business's fifty day moving average price is $7.14 and its 200-day moving average price is $8.89. Prothena Corporation plc has a twelve month low of $4.32 and a twelve month high of $22.83.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.75). Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.The firm had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. Analysts predict that Prothena Corporation plc will post -4.04 EPS for the current fiscal year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.